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Abstract
Chagas disease has been increasingly diagnosed in non-endemic countries. This is a prospective observational study performed at the Tropical
Medicine Units of the International Health Program of the Catalan Health Institute, Barcelona (PROgrama de Salud Internacional del Instituto
Catalan de la Salud, PROSICS Barcelona, Spain), that includes all patients with Chagas disease who attended from June 2007 to May 2012.
Clinical and epidemiological data were collected. Overall, 1274 patients were included, the mean age of the patients was 37.7 years, 67.5%
were women and 97% came from Bolivia. Thirteen patients had immunosuppressive conditions. The prevalence of cardiac involvement was
16.9%, lower than in previous studies performed in endemic areas (20–60%). Cardiac alterations were found in 33.8% of symptomatic and
14.1% of asymptomatic patients. The prevalence of digestive involvement was 14.8%. The rate of digestive involvement is very different among
previous studies because of different diagnostic tools and strategies used. Barium enema alterations were found in 21.4% of symptomatic and
10.3% of asymptomatic patients, and oesophageal alterations were found in 3.7% of symptomatic and in 2.3% of asymptomatic patients. As
shown in previous studies, Chagas disease in non-endemic countries affects younger patients and has lower morbidity.
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Introduction
Chagas disease, discovered in 1909 by the Brazilian physician
Carlos Chagas, is a parasitic infection caused by the hemoﬂagel-
lated protozoan Trypanosoma cruzi [1]. Despite all the efforts to
eradicate the disease, an estimated 10million people are infected
worldwide and 10 000 people die annually due to chagasic
cardiomyopathy [2]. Originally, Chagas disease was an endemic
disease of Latin America affecting rural and poor populations
living in adobe houses. Progressive urbanization of this rural
population since the 1940s has made Chagas disease an urban
disease, causing an important change in the social groups affected
by this disease [3]. The increase inmobility of populations during
the last decades is the reason for the spread of Chagas disease
outside endemic countries. As a consequence, Chagas disease
has emerged as an important public health problem in other
countries, mainly in Europe and North America [4].
Different initiatives have been launched in order to assess the
burden of Chagas disease as a public health problem in
non-endemic countries since the beginning of the 21st century.
Following European Union recommendations, some European
countries (France, Sweden, Spain and the United Kingdom) have
implemented national programmes to control transfusional
transmission of Chagas disease [5,6]. In Spain, screening for
Chagasdisease in all bloodandorgandonors coming fromendemic
areas has been mandatory since 2005. However, in relation to
mother to child transmission, only two communities (Valencia and
Catalonia) have established ofﬁcial prevention programmes [7].
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It is said that up to 30–40% of infected people will develop
cardiac or digestive involvement during their life [8]. These data
are based on classical series from endemic areas and mostly
published before 1990 [9–17]. The most recent published series
of chronic Chagas disease in non-endemic countries show a
different clinical proﬁle, with younger patients and lower
morbidity [18–23]. Although the United States has the largest
number of immigrants coming from Latin America, data regard-
ing Chagas disease in the country are scarce and come from very
limited local serological surveys in blood banks [24]. Tables 1
and 2 summarize the main information from clinical series of
Chagas disease patients in endemic and non-endemic countries.
We present clinical and epidemiological data of Trypanosoma
cruzi-infectedpatientswho attended theTropicalMedicineUnits
of the International Health Program of the Catalan Health
Institute, Barcelona (PROgrama de Salud Internacional del
Instituto Catalan de la Salud, PROSICS Barcelona, Spain).
Patients and Methods
Study population and data collection
This is a prospective observational study performed at the
Infectious Diseases Department of the Hospital Universitari
Vall d’Hebron (HUVH), a tertiary hospital, and at the
Infectious Diseases Special Program, Hospital Universitari Vall
d’Hebron-Drassanes (UMTSID), a primary care centre, both
included in PROSICS Barcelona (Spain). All adult patients
(over 18 years old) with Chagas disease attending PROSICS
Barcelona from June 2007 to May 2012 were invited to
participate and included. Clinical and epidemiological data
were collected: age, gender, country of origin, time since
arrival to our country, clinical symptoms, co-morbidities,
visceral involvement studies and completion of treatment. The
study protocol was approved by the institutional review board
of the hospital and verbal informed consent was obtained
from all patients.
Chagas disease diagnosis and visceral involvement
assessment
Diagnosis of Chagas disease was performed through two
positive serological tests according to WHO recommenda-
tions [25]: an enzyme-linked immunosorbent assay (ELISA)
with recombinant antigen (Bioelisa Chagas, Biokit, Llica
d’Amunt, Spain), and an ELISA with crude antigen (Ortho
T.cruzi ELISA, Johnson & Johnson, high wycombe, UK or
ELISA cruzi, bioMerieux, Marcy-l’Etoile, France). When
serological tests were discordant, sera were tested by an
in-house western blot method using a lysate from Trypan-
osoma cruzi epimastigotes to conﬁrm the diagnosis [26].
TABLE 1. Main clinical series of chronic Chagas disease patients in endemic areas
Reference of
publication Laranja [9] Coura [10] Coura [11] Breniere [12] Pless [13]
Country Brazil Brazil Brazil Bolivia Bolivia
Study period 1943–1955 1960–1983 1956–1971 1989 1988
Number of patients 1340 510 1070 272 103
Mean age (years) 32% of patients
over 40 years
33% of patients over 40 years 44% of patients over 40 years No data 40% of patients over
40 years
Provenance of patients No data Serological survey, blood bank Serological survey Serological survey Serological survey
Immunosuppressed patients No data No data No data No data No data
Cardiac assessment ECG ECG, chest X-ray ECG, chest X-ray ECG ECG
Cardiac form prevalence 50.9% 52.1% 40–60% 25.3% 20.3%
Gastrointestinal assessment No data Oesophagogram in all patients,
barium enema only in
symptomatic patients
X-ray of the right anterior
side of the oesophagus in
all patients
Barium enema and X-ray of
the right anterior side of the
oesophagus in all patients
Swallowing time test in all
patients
Gastrointestinal form
prevalence
No data 14.3% 9–10% 35.1% 22%
Number of treated patients No data No data No data No data No data
Reference of
publication Borges-Pereira [14] Borges-Pereira [15] Sanchez-Guillen [16]
Moretti
[17]
Country Brazil Brazil Mexico Argentina
Study period 1998 2002 2006 2010
Number of patients 270 205 71 405
Mean age (years) 62% of patients over 40 years 87% of patients over 40 years 39.4 No data
Provenance of patients Serological survey Serological survey Serological survey Serological
survey
Immunosuppressed patients No data No data No data No data
Cardiac assessment ECG ECG ECG, chest X-ray, echocardiogram ECG
Cardiac form prevalence 24.6% 30.4% 35.2% 29.2%
Gastrointestinal assessment No data No data Barium enema, oesophagogram
and oesophageal
manometry in all patients
No data
Gastrointestinal form prevalence No data No data 21.1% No data
Number of treated patients No data No data No data No data
ECG, electrocardiogram.
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Cardiac involvement was assessed through a questionnaire
on symptoms, physical examination, 12-lead electrocardiogram
and chest X-ray. An electrocardiogram was deﬁned as
pathological when at least one of the following was present:
bradycardia (<50 bpm), atrioventricular block, bundle branch
block or hemiblock, low voltages and tachyarrhythmia. Chest
X-ray was considered pathological when the cardiothoracic
ratio was greater than 0.5 (cardiac enlargement). Patients were
stratiﬁed according to the clinical Kuschnir classiﬁcation [27].
For assessment of gastrointestinal involvement, physical
examination, questionnaire on symptoms, oesophagogram
and barium enema were performed; radiological studies were
performed in all patients, even without the presence of
symptoms, based on previous studies that reported digestive
involvement in asymptomatic patients [28]. Pathological oeso-
phagogram was considered following Rezende classiﬁcation
[29]; pathological barium enema was deﬁned by dolichocolon
(length from the anus to the transition to the descending colon
>70 cm) or megacolon (sigmoid diameter >6 cm) [30].
Treatment protocol
Based on current recommendations, treatment was offered
to all adults aged 19–50 years without advanced cardiomy-
opathy, except for pregnant or lactating women [2]. Benzni-
dazole 5 mg/Kg/day divided into two or three doses for
60 days was prescribed when indicated. In some patients,
when benznidazole was not available, nifurtimox 15 mg/Kg/
day divided into three doses for 60 days was prescribed.
Patients were controlled at 15, 30 and 60 days after starting
treatment through a medical visit and blood test (including
cell blood count and general biochemistry). Adherence and
adverse events were evaluated at every visit through a
questionnaire.
Statistical analysis
Categorical data are presented as absolute numbers and
proportions, and continuous variables are expressed as means
and ranges. SPSS software for Windows (Version 15.0; SPSS
Inc, Chicago, IL, USA) was used for statistical analyses.
Results
During this 5-year period, 1274 patients were included (600
patients from HUVH and 674 from UMTSID). Baseline
characteristics of patients are summarized in Table 3. The
TABLE 2. Main clinical series of chronic Chagas disease patients in non-endemic areas
Reference of
publication Mu~noz [18] Lescure [19] Perez-Ayala [20] Valerio [21] Jackson [22] Ramos [23]
Country Spain France Spain Spain Switzerland Spain
Country of origin of patients Bolivia 86.6% Bolivia 87.4% Bolivia 97% Bolivia 95% Bolivia 93.4% Bolivia 78.9%
Study period 2004–2007 2008–2009 2003–2009 2005–2009 1979–2011 2002–2011
Number of patients 202 60 357 100 258 128
Mean age (years) 36 33 36 38.2 41 35
Provenance of patients TMU TMU TMU, PCC, blood bank TMU, PCC PCC, blood bank Hospital with no TMU
Immunosuppressed patients 3 HIV, 3 oncological
patients
No data 4 HIV No data 1 heart
transplantation
1 HIV
Cardiac assessment ECG, chest X-ray Clinical symptoms ECG, echocardiogram ECG,
echocardiogram
No data ECG, chest X-ray,
echocardiogram
Cardiac form prevalence 19% 23.6% 18.6% 49% 20.1% 24.1%
Gastrointestinal assessment Barium enema and
oesophagogram, only
in symptomatic
patients
Clinical symptoms Barium enema,
oesophagogram and
oesophageal manometry,
only in symptomatic
patients
No data No data Barium enema and
oesophagogram,
only in symptomatic
patients
Gastrointestinal form prevalence 9% 22% 5.1% No data 0.7% 0.9%
Number of treated patients No data No data 195 (54.6%) No data 129 (50%) 76 (59.3%)
TMU, Tropical Medicine Units; PCC, Primary Care Centres; MTCTPP, mother to child transmission prevention programme; HIV, human immunodeﬁciency virus; ECG,
electrocardiogram.
TABLE 3. Baseline characteristics of patients with Chagas
disease who attended PROSICS Barcelona (2007–2012)
Characteristics
Overall patients
(n = 1274)
Female sex 860 (67.5%)
Age, years 37.7 (18–81)
Country of origin
Bolivia 1236 (97%)
Argentina 16 (1.3%)
Ecuador 6 (0.5%)
Paraguay 5 (0.4%)
Other countriesa 11 (0.8%)
Time of diagnosis since arrival in our country, years 5.1 (0–38)
Provenance
Blood donors 110 (8.6%)
Volunteer screening in Tropical Medicine Units 605 (47.5%)
Volunteer screening at Primary Care Centres 464 (36.4%)
Mother to child transmission prevention programme 52 (4.1%)
Emergency service or hospitalization 35 (2.7%)
Other 8 (0.6%)
Co-morbidities causing immunosuppression
No co-morbidity 1261 (98.9%)
HIV infection 5 (0.4%)
Haematological malignancy 2 (0.2%)
Solid organ transplantation 2 (0.2%)
Other 4 (0.3%)
Data are reported as number (%) of patients or mean value (range).
aOther countries: three patients from Colombia, two patients from Honduras,
Spain and Brazil, and one patient from Chile and Venezuela.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 706–712
708 Clinical Microbiology and Infection, Volume 20 Number 7, July 2014 CMI
mean age of patients was 37.7 (18–81) years and 860 (67.5%)
were women. The vast majority came from Bolivia (1236
patients, 97%) and at the time of the ﬁrst visit the mean
duration of residence in our country was 5.1 (0–38) years.
Most of them (605 patients, 47.5%) were Latin American
immigrants coming to the Tropical Medicine Units (both
HUVH and UMTSID) to take part in volunteer Chagas disease
screening. The remaining patients were referred to the
Tropical Medicine Units when diagnosed in other institutions
(blood banks, primary care centres and mother to child
transmission prevention programme). Thirteen (1.1%) patients
had immunosuppressive conditions.
Visceral abnormalities are summarized in Tables 4 and 5.
The most common symptoms among patients in our study
were constipation (21.8%), chest pain (6.5%), dyspnoea (5.2%)
and palpitations (5.1%). Cardiac assessment could be per-
formed in 1125 out of 1274 patients, of whom 190 (16.9%) had
cardiac abnormalities, mostly characterized by electrocardio-
graphic alterations. Among patients with any symptom
suggestive of cardiac involvement (dyspnoea, chest pain,
palpitation and syncope), 54 out of 160 (33.8%) patients had
cardiac abnormalities, and 136 out of 965 (14.1%) asymptom-
atic patients presented cardiac alterations. Eight patients
needed pacemaker implantation at the time of diagnosis or
during follow-up, mostly due to third-degree atrioventricular
block. Gastrointestinal assessment could be performed in 1041
out of 1274 patients. One hundred and ﬁfty-four (14.8%)
patients showed colonic or oesophageal involvement: 135
(13%) patients had a pathological barium enema (104 patients
with dolichocolon and 31 patients with megacolon) and 25
(2.4%) patients had oesophageal alterations according to
Rezende classiﬁcation. Barium enema abnormalities were
found in 53 out of 248 (21.4%) patients complaining of
constipation, and in 82 out of 793 (10.3%) asymptomatic
patients. Alterations in the oesophagogram were found in
three out of 82 (3.7%) patients with any symptom suggestive of
oesophageal involvement (dysphagia, dyspepsia and gastro-
esophageal reﬂux), and in 22 out of 959 (2.3%) asymptomatic
patients.
Twenty-nine patients had received speciﬁc treatment
before inclusion in the study. Of the remaining patients, 636
out of 1245 (51.1%) received treatment during the study
period. Among these treated patients, benznidazole was
prescribed in 629 (98.9%) patients and seven (1.1%) patients
received nifurtimox. Overall, 462 (72.6%) patients presented at
least one adverse effect: 337 (53%) patients presented skin
toxicity, 131 (20.6%) patients had gastrointestinal adverse
events, 73 (11.5%) patients presented transaminase elevation,
64 (10%) patients had neurological disorders (peripheral
neuropathy and dysgeusia), 22 (3.5%) patients presented a
decrease in neutrophil cell count and 185 (29.1%) complained
of general adverse effects (headache, somnolence, weakness
and arthromyalgia). Of the 636 treated patients, 523 (82.2%)
completed the treatment; treatment was stopped in 87
(13.7%) patients due to toxicity; 26 (4.1%) patients received
incomplete treatment due to causes not related to adverse
events (mostly because they were lost to follow-up during
treatment). The most frequent reasons for not receiving
treatment were lost to follow-up before starting treatment
TABLE 4. Cardiac involvement of patients with Chagas
disease who attended PROSICS Barcelona (2007–2012)
Clinical ﬁndings
Number of
patients (%)
Clinical symptoms (n = 1274)
Chest pain 83 (6.5%)
Dyspnoea 66 (5.2%)
Palpitations 65 (5.1%)
Syncope 14 (1.1%)
Stroke 2 (0.2%)
Any cardiac symptom 176 (13.8%)
Cardiac involvement (n = 1125) 190 (16.9%)
Kuschnir classiﬁcationa (n = 1125)
0 935 (83.1%)
I 169 (15%)
II 10 (0.9%)
III 11 (1%)
Electrocardiographic alterations (n = 190)
Sinus bradycardia 69 (36.3%)
Right bundle branch block 68 (35.8%)
Left anterior hemiblock 56 (29.5%)
Low voltages 14 (7.4%)
Third-degree atrioventricular block 7 (3.7%)
First-degree atrioventricular block 6 (3.1%)
Left bundle branch block 3 (1.6%)
Left posterior hemiblock 2 (1%)
aKuschnir classiﬁcation: group 0, normal electrocardiogram and normal heart size
in the chest X-ray; group I, abnormal electrocardiogram and normal heart size;
group II, heart enlargement in the chest X-ray; group III, congestive heart failure.
TABLE 5. Gastrointestinal involvement of patients with
Chagas disease who attended PROSICS Barcelona (2007–
2012)
Clinical ﬁndings
Number of
patients (%)
Clinical symptoms (n = 1274)
Constipation 278 (21.8%)
Dysphagia 41 (3.2%)
Dyspepsia 40 (3.1%)
Gastroesophageal reﬂux 22 (1.7%)
Any digestive symptom 333 (26.1%)
Gastrointestinal involvement (n = 1041) 154 (14.8%)
Barium enema (n = 1041)
Normal 906 (87%)
Dolichocolon 104 (10%)
Colonic dilatation (sigmoid diameter >6 cm) 31 (3%)
Oesophagograma (n = 1041)
Normal 1016 (97.6%)
Rezende I 21 (2%)
Rezende II 3 (0.3%)
Rezende II 1 (0.1%)
Rezende IV 0 (0%)
aRezende classiﬁcation: group I, oesophagus with normal calibre but with slow
contrast progression and small retention of contrast 1 min after ingestion; group
II, oesophagus with small to moderate dilatation and considerable radiological
contrast retention; group III, hypotonic oesophagus with important dilatation and
great retention of contrast; group IV, oesophagus elongated that lies over the
diaphragm with great retention of contrast (dolico-megaoesophagus).
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and the worldwide stock shortage of benznidazole from
August 2011 to November 2012.
Discussion
In our study we present 1274 patients with Chagas disease
who attended PROSICS Barcelona during the last 5 years; to
the best of our knowledge, this is the largest cohort of
Trypanosoma cruzi-infected patients described in a non-en-
demic country. When comparing most relevant clinical series
of Chagas disease patients in Europe, a considerable diversity
has been observed in the patient proﬁles from country to
country. This diversity could be explained by the heterogeneity
in the geographical distribution of the Latin American popu-
lation living in Europe and the different prevalence rates for
Trypanosoma cruzi infection in their countries of origin, even
between different regions of the same country [31]. Further-
more, the great regional diversity of Chagas disease morbidity
is increased by the different diagnostic criteria used in each
country. We could have different ‘Chagas disease variants’
depending on the country.
The prevalence of cardiac involvement in most represen-
tative non-endemic series is around 16–20%, while the
prevalence in endemic series is up to 60%. As has been
proposed, this difference is probably because those who
migrate seeking work opportunities are usually healthy and
younger [18,20]. In our study, even though the prevalence of
cardiac involvement was lower than expected, it had a high
impact in terms of morbidity, with 21 (1.9%) patients in groups
II and III according to Kuschnir classiﬁcation and eight patients
who needed pacemaker implantation.
Gastrointestinal involvement rates were more heteroge-
neous than cardiac involvement rates. The prevalence of
digestive involvement in endemic countries ranges from 10%
to 35%, whereas the prevalence in most non-endemic areas is
lower (0.7–9%). These differences could be explained by two
factors: the populations studied and diagnostic tests used. In
most non-endemic series, radiological studies are performed
only in symptomatic patients, so the prevalence of digestive
involvement is probably under-diagnosed. In our study, we
performed radiological investigations in all patients regardless
of the presence of digestive symptoms. This strategy could
explain the high proportion of digestive involvement found in
our study when compared with other non-endemic studies.
Dolichocolon was the most frequent ﬁnding; recent studies
suggest that colonic elongation (dolichocolon) precedes dila-
tation and is the ﬁrst step in the chagasic colonic involvement.
However, in the oesophagus the lengthening appears at the
end, when the megaoesophagus is established [32].
Cardiac assessment through electrocardiogram and chest
X-ray should be offered to all infected patients, regardless of
symptoms, because about 15% of asymptomatic participants
had some cardiac abnormalities and tests are not invasive. In
contrast, the prevalence of oesophageal abnormalities has
been very low (2.4%), suggesting that systematic oesophageal
assessment would not be cost-effective in asymptomatic
patients. Finally, colonic radiological evaluation could be
considered in asymptomatic patients because abnormalities
are found in about 10%, but would be somewhat limited due to
its invasiveness and its questionable impact on clinical
management.
In our series we describe 13 patients in whom Chagas
disease coexists with immunosuppressive conditions. Clini-
cians should be aware that Chagas disease in immunosup-
pressed patients may reactivate with high parasitaemia and
more severe manifestations, mainly meningoencephalitis and
myocarditis; none of the 13 patients with immunosuppressive
conditions in our study presented reactivation of Chagas
disease. This circumstance has increasingly been reported in
the literature and speciﬁc protocols for diagnosis and
management are needed [33].
Information on the efﬁcacy of benznidazole for treating
adult patients with chronic Chagas disease is scarce and
recommendations are based on only a few studies [34,35].
Treatment should generally be offered to adults under
50 years old without advanced cardiomyopathy. However,
benznidazole has a high adverse events rate, ranging from 30%
to 57% depending on the studies. Unfortunately, no informa-
tion is available about its mechanisms of toxicity [34,36,37]. In
our study, 13.7% of treated patients could not complete
treatment due to toxicity. More studies are needed to
improve knowledge on the mechanisms of action and toxicity
of benznidazole, in order to reduce or prevent side-effects.
One of the most important limitations of our study is the
number of patients lost during follow-up, especially before
starting speciﬁc treatment. This could be because most
immigrants come to Spain seeking opportunities and have
great mobility, and reinforces the need for a multidisciplinary
approach, with strong links between hospitals and primary
healthcare professionals. Another limitation is that symptoms
suggestive of visceral involvement may change during follow-up
and they are perceived by patients in very different ways,
making the evaluation of symptoms difﬁcult.
In summary, as previously reported, our study shows that
the clinical proﬁle of Chagas disease in non-endemic areas is
different to that in endemic areas, with lower morbidity and
affecting younger patients. Countries that receive Latin
American immigration have the interesting challenge of
adapting their public health systems to make the control of
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Chagas disease possible: blood donor screening, donor and
recipient screening for organ transplantation, mother to child
transmission prevention programmes, and trained physicians
to diagnose and manage Chagas disease. New and speciﬁc
strategies are needed to involve all the participants (medical
personnel, patients, governors and decision makers) in order
to decrease the under-diagnosis of this disease. Protocols must
be designed in each country, considering the main health
determinants of the Latin American population in each area or
country (country of origin, age and gender), and a consensus in
the diagnosis and management of Chagas disease is needed.
Longer prospective studies are needed to evaluate the
evolution of the disease out of endemic areas, with better
access to health systems and different environmental inﬂu-
ences.
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